“Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis”, J of Skin, vol. 8, no. 6, p. s442, Nov. 2024, doi: 10.25251/skin.8.supp.442.